These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 28040858)

  • 1. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
    Echavarria I; Granja M; Bueno C; Lopez-Tarruella S; Peinado P; Sotelo M; Jerez Y; Moreno F; Torres G; Lobo M; Marquez-Rodas I; Del Monte-Millan M; Martín M; García-Saenz JA
    Breast Cancer Res Treat; 2017 Feb; 162(1):181-189. PubMed ID: 28040858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
    Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
    Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: An Indian experience.
    Tiwari A; Gogia A; Deo S; Shukla NK; Mathur S; Sharma DN
    Indian J Cancer; 2017; 54(1):343-346. PubMed ID: 29199719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
    Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
    Bayraktar S; Gonzalez-Angulo AM; Lei X; Buzdar AU; Valero V; Melhem-Bertrandt A; Kuerer HM; Hortobagyi GN; Sahin AA; Meric-Bernstam F
    Cancer; 2012 May; 118(9):2385-93. PubMed ID: 21953213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.
    Kolberg HC; Akpolat-Basci L; Stephanou M; Aktas B; Hannig CV; Liedtke C
    Breast Care (Basel); 2016 Oct; 11(5):323-327. PubMed ID: 27920624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Docetaxel, carboplatin plus trastuzumab as neoadjuvant setting in patients with early-stage human epidermal growth factor receptor 2 positive breast cancer: a retrospective analysis].
    Xin L; Zhang H; Zhang S; Cheng YJ; Liu Q; Xu L; Ye JM; Li T; Duan XN; Liu YH; Li ZH
    Zhonghua Wai Ke Za Zhi; 2021 Mar; 59(3):222-227. PubMed ID: 33685057
    [No Abstract]   [Full Text] [Related]  

  • 11. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
    Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
    Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
    Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
    Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience with pertuzumab and trastuzumab combined with chemotherapy in neoadjuvant treatment for patients with early-stage HER2-positive breast cancer: the NEOPERSUR study.
    Falcón González A; Cruz Jurado J; Llabrés Valenti E; Urbano Cubero R; Álamo de la Gala MC; Martínez Guisado MA; Álvarez Ambite R; Rodríguez González CJ; Amérigo Góngora M; Rodríguez Pérez L; López Álvarez P; Sánchez Rovira P; González Flores E; Henao Carrasco F; Bayo Calero J; Valero Arbizu M; Quílez Cutillas A; Salvador Boffil J; Rubio Pérez E; Ruiz-Borrego M
    Clin Transl Oncol; 2024 Sep; 26(9):2217-2226. PubMed ID: 38538968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
    A L-Tweigeri T; AlSayed A; Alawadi S; Ibrahim M; Ashour W; Jaafar H; Abulkhair O; A L-Abdulkarim H; Khalid H; Ajarim D;
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):147-53. PubMed ID: 26563257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Wang RX; Chen S; Jin X; Chen CM; Shao ZM
    Breast Cancer Res Treat; 2017 Jan; 161(2):259-267. PubMed ID: 27885439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.
    Huang L; Chen S; Yang W; Xu B; Huang T; Yang H; Zheng H; Wang Y; Song E; Zhang J; Cui S; Pang D; Tang L; Lei Y; Geng C; Shao Z
    Oncotarget; 2015 Jul; 6(21):18683-92. PubMed ID: 26084292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70).
    Hanusch C; Schneeweiss A; Loibl S; Untch M; Paepke S; Kümmel S; Jackisch C; Huober J; Hilfrich J; Gerber B; Eidtmann H; Denkert C; Costa S; Blohmer JU; Engels K; Burchardi N; von Minckwitz G
    Clin Cancer Res; 2015 Jul; 21(13):2924-31. PubMed ID: 25825476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Giacchetti S; Hamy AS; Delaloge S; Brain E; Berger F; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Saghatchian M; Lerebours F; Mazouni C; Tembo O; Espié M; Reyal F; Marty M; Asselain B; Pierga JY
    Eur J Cancer; 2017 Apr; 75():323-332. PubMed ID: 28279941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.